Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus

Fig. 2

Cinaciguat treatment alleviates diabetes mellitus related oxidative stress. a Representative images of nitrotyrosine (NT) immunohistochemistry. Magnification: ×200, Scale bar 40 µm. b Quantification of NT immunohistochemistry (P value of diabetes × treatment interaction in the two-factorial ANOVA, Pinteraction <0.001) (n = 9–11/group). (c) Relative mRNA expression of catalase, gluthatione-reductase (Pinteraction = 0.046), heat shock 70 kD protein 1A (HSP70a1) (Pinteraction = 0.021), superoxide dismutase (SOD)-2 and thioredoxin-1 (n = 5–6/group). Groups: vehicle-treated control (Co), cinaciguat-treated control (CoCin), vehicle-treated diabetic (DiabCo) and cinaciguat-treated diabetic (DiabCin). Bar graphs represent mean ± SEM. *P < 0.05 vs. Co, P < 0.05 vs. DiabCo (Tukey HSD test)

Back to article page